Pelabresib,Ruxolitinib
morphosys
['morphosys']
morphosys presents multiple analyses of the manifest phase 2 trial investigating the potential of pelabresib in the treatment of myelofibrosis at eha 2022 
Pharmaceutical News - Direct Information